Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Post-Transplant Events

Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole

Bone Marrow Transplantation volume 40, pages 451–456 (2007)Cite this article

Abstract

Seventy-one allograft recipients receiving voriconazole, in whom complete clinical, microbiologic and pharmacokinetic data were available, were studied to determine the efficacy of voriconazole in preventing fungal infections. The length of voriconazole therapy was 6–956 days (median 133). The total number of patient-days on voriconazole was 13 805 (∼38 years). A total of 10 fungal infections were seen in patients on voriconazole (18% actuarial probability at 1 year): Candida glabrata (n=5), Candida krusei (n=1), Cunninghamella (n=1), Rhizopus (n=2) and Mucor (n=1). Two of the four zygomycosis cases were preceded by short durations of voriconazole therapy, but prolonged itraconazole prophylaxis. The plasma steady-state trough voriconazole levels around the time the infection occurred were <0.2, <0.2, 0.33, 0.55, 0.63 and 1.78 μg/ml in the six candidiasis cases. Excluding the four zygomycosis cases, all the six candidiasis cases were seen among the 43 patients with voriconazole levels of ⩽2 μg/ml and none among the 24 with levels of >2 μg/ml (P=0.061). We conclude that voriconazole is effective at preventing aspergillosis. However, breakthrough zygomycosis is seen in a small proportion of patients. The role of therapeutic voriconazole monitoring with dose adjustment to avoid breakthrough infections with fungi that are otherwise susceptible to the drug needs to be explored prospectively.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Nucci M, Marr KA . Emerging fungal infections. Clin Infect Dis 2005; 41: 521–526.

    Article  PubMed  Google Scholar 

  2. Singh N, Paterson DL . Aspergillus Infections in transplant patients. Clin Microbiol Rev 2005; 18: 44–69.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Sullivan KM, Dykewicz CA, Longworth DL, Boeckh M, Baden LR, Rubin RH et al. Preventing opportunistic infections after hematopoietic stem cell transplantation: The Centers for Disease Control, Infectious Disease Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and beyond. Hematology (Am Soc Hematol Educ Program) 2001, 392–421.

    Article  Google Scholar 

  4. Trifilio SM, Verma A, Mehta J . Antimicrobial prophylaxis in hematopoietic stem cell transplant recipients: heterogeneity of current clinical practice. Bone Marrow Transplant 2004; 33: 735–739.

    Article  CAS  PubMed  Google Scholar 

  5. Andes D, Forrest A, Lepak A, Nett J, Marchillo K, Lincoln L . Impact of antimicrobial dosing regimen on evolution of drug resistance in vivo: fluconazole and Candida albicans. Antimicrob Agents Chemother 2006; 50: 2374–2383.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408–415.

    Article  CAS  PubMed  Google Scholar 

  7. Ostrosky-Zeichner L, Rex JH, Pappas PG, Hamill RJ, Larsen RA, Horowitz HW et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrobiol Agents Chemother 2003; 47: 3149–3154.

    Article  CAS  Google Scholar 

  8. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346: 225–234.

    Article  CAS  PubMed  Google Scholar 

  9. Smith J, Safdar N, Knasinski V, Simmons W, Bhavnani SM, Ambrose PG et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006; 50: 1570–1572.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Marr KA, Crippa F, Leisenring W, Hoyle M, Boeckh M, Balajee SA et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004; 103: 1527–1533.

    Article  CAS  PubMed  Google Scholar 

  11. Trifilio S, Ortiz R, Pennick G, Verma A, Pi J, Stosor V et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2005; 35: 509–513.

    Article  CAS  PubMed  Google Scholar 

  12. Pennick GJ, Clark M, Sutton DA, Rinaldi MG . Development and validation of a high-performance liquid chromatography assay for voriconazole. Antimicrob Agents Chemother 2003; 47: 2348–2350.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Siwek GT, Pfaller MA, Polgreen PM, Cobb S, Hoth P, Magalheas-Silverman M et al. Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis. Diagn Microbiol Infect Dis 2006; 55: 209–212.

    Article  CAS  PubMed  Google Scholar 

  14. Marr KA, Seidel K, Slavin MA, Bowden RA, Schoch HG, Flowers ME et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000; 96: 2055–2061.

    CAS  PubMed  Google Scholar 

  15. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41: 634–653.

    Article  PubMed  Google Scholar 

  16. Kontoyiannis DP, Lewis RE . Invasive zygomycosis: update on pathogenesis, clinical manifestations, and management. Infect Dis Clin North Am 2006; 20: 581–607.

    Article  PubMed  Google Scholar 

  17. Marty FM, Cosimi LA, Baden LR . Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004; 350: 950–952.

    Article  CAS  PubMed  Google Scholar 

  18. Kontoyiannis DP, Lionakis MS, Lewis RE, Chamilos G, Healy M, Perego C et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case–control observational study of 27 recent cases. J Infect Dis 2005; 191: 1350–1360.

    Article  PubMed  Google Scholar 

  19. Verma A, Williams S, Trifilio S, Zembower T, Mehta J . Successful treatment of concomitant pulmonary zygomycosis and aspergillosis with a combination of amphotericin B lipid complex, caspofungin, and voriconazole in a patient on immunosuppression for chronic graft-versus-host disease. Bone Marrow Transplant 2004; 33: 1065–1066.

    Article  CAS  PubMed  Google Scholar 

  20. Marr KA, Seidel K, White TC, Bowden RA . Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000; 181: 309–316.

    Article  CAS  PubMed  Google Scholar 

  21. www.fda.gov/ohrms/dockets/ac/01/briefing/3792b2_02_FDA-voriconazole.htm (Accessed 9 November 2006; page search term ‘Voriconazole Efficacy Response Assessment’).

  22. Pfaller MA, Diekema DJ, Rex JH, Espinel-Ingroff A, Johnson EM, Andes D et al. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol 2006; 44: 819–826.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Boogaerts MA, Verhoef GE, Zachee P, Demuynck H, Verbist L, De Beule K . Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycoses 1989; 32 (Suppl 1): 103–108.

    Article  PubMed  Google Scholar 

  24. Berenguer J, Ali NM, Allende MC, Lee J, Garrett K, Battaglia S et al. Itraconazole for experimental pulmonary aspergillosis: comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole concentrations in plasma. Antimicrob Agents Chemother 1994; 38: 1303–1308.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Glasmacher A, Hahn C, Leutner C, Molitor E, Wardelmann E, Losem C et al. Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses 1999; 42: 443–451.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

No financial support was received for this work.

Author information

Authors and Affiliations

  1. Northwestern Memorial Hospital, Chicago, IL, USA

    S Trifilio & J Pi

  2. The Feinberg School of Medicine, Northwestern University, Chicago, IL, USA

    S Singhal, S Williams, O Frankfurt, L Gordon, A Evens, J Winter, M Tallman & J Mehta

Authors
  1. S Trifilio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Singhal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Williams
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. O Frankfurt
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L Gordon
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A Evens
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J Winter
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M Tallman
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J Pi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. J Mehta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J Mehta.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Trifilio, S., Singhal, S., Williams, S. et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant 40, 451–456 (2007). https://doi.org/10.1038/sj.bmt.1705754

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705754

Keywords

This article is cited by

Search

Advanced search

Quick links